SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Waiver Solution in Public Health and Pharmaceutical Domain Under TRIPS Agreement
9 references·1 citing·23 second hop
Waiver Solution in Public Health and Pharmaceutical Domain Under TRIPS Agreement (2011)Waiver Solution in Public Health and Phar…Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options (2010)Compulsory Licensing of Paten…Compulsory Licenses: The Dangers Behind the Current Practice (2009)Compulsory Licenses: The Dang…Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options (2009)Comment: Compulsory Licensing…Unsettled International Intellectual Property Issues (2008)Unsettled International Intel…Finding flaws: the limitations of compulsory licensing for improving access to medicines--an international comparison. (2008)Finding flaws: the limitation…The International Enclosure Movement (2007)The International Enclosure M…The WTO Medicines Decision: World Pharmaceutical Trade and the Protection of Public Health (2005)The WTO Medicines Decision: W…Pandemics and Panaceas: The World Trade Organization's Efforts to Balance Pharmaceutical Patents and Access to AIDS Drugs (2004)Pandemics and Panaceas: The W…Cheap Drugs at What Price to Innovation: Does the Compulsory Licensing of Pharmaceuticals Hurt Innovation (2003)Cheap Drugs at What Price to …Vaccine nationalism and equitable access to COVID-19 pharmaceuticals: TRIPS Agreement under trial (again) (2021)Vaccine nationalism and equit…Agreement on trade-related aspects of intellectual property rights (2000)Information Feudalism: Who Owns the Knowledge Economy? (2003)The price of innovation: new estimates of drug development costs (2003)GLOBAL HEALTH IMPACT: A BASIS FOR LABELING AND LICENSING CAMPAIGNS? (2012)The COVID-19 Innovation System (2021)Mitigation Pathways Compatible with Long-term Goals (2023)Intellectual Property Rights in the Global Economy (2000)Drug development for neglected diseases: a deficient market and a public-health policy failure (2002)The Political Economy of AIDS Treatment: Intellectual Property and the Transformation of Generic Supply (2007)Global Health Governance (2008)Defining Health Diplomacy: Changing Demands in the Era of Globalization (2011)The Doha Declaration on the TRIPS Agreement and Public Health: Lighting a Dark Corner at the WTO (2002)TRIPS-Plus Provisions in FTAs: Recent Trends (2006)Facilitating Access to Cross-Border Supplies of Patented Pharmaceuticals: The Case of the COVID-19 Pandemic (2020)Pandemic science and commercial values: An institutional account of values in science (2023)The Problems with Patents: A Less than Optimistic Reading of the Future (2009)Intellectual Property and Economic Development in Sub‐Saharan Africa (2011)Wandering footloose: Traditional knowledge and the “Public Domain” revisited (2018)Compulsory Licensing in Canada and Thailand: Comparing Regimes to Ensure Legitimate Use of the WTO Rules (2009)Investments in Pharmaceuticals Before and After TRIPS (2009)Do patent pledges accelerate innovation? (2023)Mandatory Licensing Under Patent Law and Competition Law: Different Concerns, Complementary Roles (2014)Welfare effects of compulsory licensing (2015)
this work references cited by second hop

References

  • 2005The WTO Medicines Decision: World Pharmaceutical Trade and the Protection of Public Health193 cited
  • 2009Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options109 cited
  • 2003Cheap Drugs at What Price to Innovation: Does the Compulsory Licensing of Pharmaceuticals Hurt Innovation103 cited
  • 2007The International Enclosure Movement43 cited
  • 2010Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options33 cited
  • 2004Pandemics and Panaceas: The World Trade Organization's Efforts to Balance Pharmaceutical Patents and Access to AIDS Drugs31 cited
  • 2008Unsettled International Intellectual Property Issues24 cited
  • 2009Compulsory Licenses: The Dangers Behind the Current Practice20 cited
  • 2008Finding flaws: the limitations of compulsory licensing for improving access to medicines--an international comparison.13 cited

Cited by

  • 2021Vaccine nationalism and equitable access to COVID-19 pharmaceuticals: TRIPS Agreement under trial (again)9 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work